GlassScriptPhysician profile
David S Longley
NPI 1265559645
$1,406.03
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $380 · 2023: $294 · 2024: $180 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.74 | 2021-2024 | Xifaxan |
| Novo Nordisk INC | $195.00 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $185.43 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $183.18 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.43 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $131.98 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $103.14 | 2021-2023 | Shingrix, Arexvy |
| Abbvie INC. | $79.06 | 2023-2024 | |
| Pfizer INC. | $48.89 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $44.25 | 2021-2022 | |
| Abbott Laboratories | $42.83 | 2021-2023 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $29.72 | 2021 | |
| Amgen INC. | $18.84 | 2024 | Repatha, Otezla |
| Corcept Therapeutics | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Longley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.